- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04350788
Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using A Couple-focused Web-based Tailored Symptom Self-management Program (SCP)
The purpose of this research study is to examine the feasibility of the enhanced survivorship care plans (ESCPs, regular SCPs with the a web-based couple-focused symptom self-management project (PERC) or National Cancer Institute prostate cancer web links) and to conduct an initial benefit assessment of enhanced survivorship care plans among prostate cancer patients transitioning from active treatment to post-treatment self-management, and their partners.
Participation of this study lasts for about for 16 weeks. Depending on participants' need for information, it takes 10-30 minutes of their time each week to review the information about prostate cancer.
Eligible and consented patients with newly treated localized prostate cancer and your partner (couples) are randomly assigned to the regular survivorship care plan (SCPs) with the NCI website or the enhanced survivorship care plans (SCP plus the web-based prostate cancer education program, PERC) groups. They complete baseline (T1, prior to randomization) and 4-month post-T1 follow-up measures (T2).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Methods: A two-group randomized controlled pretest-posttest design will be used and collect data at baseline (T1) and 4 months later (T2) among 50 patients completing initial treatment for localized prostate cancer and their partners. First, the investigators will assess the feasibility of ESCP by recruitment, enrollment, and retention rates, program satisfaction with the ESCP, and perceived ease of use of the ESCP. To achieve the secondary aim, the ESCP users will be compared with the standardized SCP users and assess their primary outcomes of QOL (overall, physical, emotional, and social QOL), secondary outcomes (reduction in negative appraisals and improvement in self-efficacy, social support, and health behaviors to manage symptoms), and number of visits to post-treatment care services at T1 and T2. The primary and secondary outcomes are assessed using measurements with sound psychometrical properties. The investigators will use a qualitative and quantitative mixed methods approach to achieve the research aims.
Conclusions: The results from this study will help design a definitive randomized trial to test the efficacy of the ESCPs, a potentially scalable program, to enhance supportive care for prostate cancer patients and their families.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27559
- University of North Carolina at Chapel Hill
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Eligibility included men who:
- were diagnosed with localized PC;
- were within 16 weeks of completing their initial curative intent treatment [26] at genitourinary and radiation oncology clinics at two comprehensive cancer centers in the U.S southeast;
- were not treated for another cancer in last year; and
- had a partner > 18 years of age not receiving cancer treatment.
Exclusion Criteria:
- Either member of couple unable to speak English
- Unwilling/unable to provide Informed Consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore placebo: Survivorship Care Plan (SCP)
The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
|
Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care
|
Sperimentale: Enhanced SCP (ESCP)
ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.
|
In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers.
Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Potentially Eligible Participants Actually Enrolled Into the Study
Lasso di tempo: after participants completed baseline survey
|
Will evaluate the percentage of patients and partners successfully consented and completing the baseline survey among all people approached for the study
|
after participants completed baseline survey
|
Percentage of Participants Enrolled Who Remained in the Study and Completed the Post-Intervention Follow-Up Survey
Lasso di tempo: during 4-month study period
|
Will evaluate the percentage of participants successfully following protocol, defined as completing the Follow-Up survey at the end of the study period among those who have been enrolled into the study (who completed the baseline).
|
during 4-month study period
|
Percentage of Participants That Used the Web-Based Intervention Sessions That Are Consistent With Patient-Reported Symptoms
Lasso di tempo: during 4-month study period
|
The usage of Web-Based Intervention Sessions is determined by the percentage of participants who logged into the study website among those who have been randomly assigned to the intervention group.
Patient-Reported Symptoms are determined by patient's responses on their appraisal of prostate cancer symptoms and general symptoms.
1=patient reported the symptom and the symptom webpage reviewed; 0=patient reported the symptom and no related webpage reviewed OR patient did not report the symptom but the webpage reviewed
|
during 4-month study period
|
Participant Satisfaction Scores
Lasso di tempo: at the 4 month followup
|
Program satisfaction determined by the 11-item Participant Satisfaction Scale measured the level of program satisfaction.
The first to tenth items ranged from 1=not satisfied to 5=extremely satisfied.
The eleventh item ranged from 1=extremely not to 4=definitely yes.
Higher total score indicates greater program satisfaction
|
at the 4 month followup
|
Perceived Ease of Use Score
Lasso di tempo: at the 4 month followup
|
The 16-item Program Usability measures participants' assessment of their agreement with the ease of use of the program in terms of its general features, content, and navigation.
The ranges of the total scores are (3,15), (4,20), (9,45) for general features, content, and navigation, respectively.
The score of individual item ranges from1=strongly disagree to 5=strongly agree.
Higher score indicates greater perceived ease of use.
|
at the 4 month followup
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in FACT-G Scores
Lasso di tempo: Baseline upon enrollment, Month 4
|
Change in QOL determined using the Functional Assessment of Cancer Therapy General Scale (FACT-G) v.4, a 27-item measure yielding total score and scores for physical, social/family, emotional, and functional well-being of demonstrated reliability, validity, and sensitivity to change.
FACT-G consists of 4 subscales: physical well-being (PWB), functional well-being (FWB), emotional well-being (EWB) and social well-being (SWB).
Scores on the four subscales are summed to produce a total score ranging from 0 to 108 with higher scores indicating better quality of life.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in Appraisal of Prostate Cancer-Specific Symptoms
Lasso di tempo: Baseline upon enrollment, Month 4
|
The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment.
EPIC will be used to measure change in appraisal of symptoms scores among patients from Baseline (T1) to T2 (4 months post T1).
EPIC contains 26 items within 5 domains: Urinary Incontinence, Urinary Irritative/Obstructive, Bowel, Sexual, and Hormonal.
Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing opposite results by role: patient with better appraisal of symptoms and partner with worse appraisal of symptoms.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in Appraisal of General Symptoms
Lasso di tempo: Baseline upon enrollment, Month 4
|
The 19-item Risk for Distress-general symptoms is a subscale of the Risk for Distress Scale.
It measures how much trouble the participant has with the general symptoms such as pain, fatigue, and etc.
The total score ranges between 0 and 38, with higher scores indicating worse appraisal of symptoms.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Healthcare Utilization Extracted From Electronic Medical Record
Lasso di tempo: during the first 10 months after participants completed baseline survey
|
The total number of prostate cancer-related followup visits, emergency room use and readmissions.
|
during the first 10 months after participants completed baseline survey
|
Change in Self-Efficacy Scores From Baseline to 4-Months Post Baseline
Lasso di tempo: Baseline upon enrollment, Month 4
|
The Lewis Cancer Self-Efficacy used to measure change in participants' feelings of self-efficacy in dealing with the patient's cancer diagnosis and treatment from Baseline (T1) to T2 (4 months post T1).
Participants rate statements about how confident they feel on a scale from 1 to 10, where higher scores indicate higher self-efficacy.
|
Baseline upon enrollment, Month 4
|
Change in PROMIS Social Support-Informational Support From Baseline to 4-Months Post-Baseline
Lasso di tempo: Baseline upon enrollment, Month 4
|
The Patient-Reported Outcomes Measurement Information System (PROMIS) Informational Support Short Form 8a will be used to assess changes in patient and partner reported informational support system using a 5-point Likert scale from Baseline (T1) to T2 (4 months post T1).
The total score range: 8-40.
Higher scores indicate more informational support.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in PROMIS Social Support-Emotional Support From Baseline to 4-months Post-Baseline
Lasso di tempo: Baseline upon enrollment, Month 4
|
The PROMIS Emotional Support System-Short Form 8a will be used to assess changes in the self-reported emotional support system of patients and their partners using a 5-point Likert scale from Baseline (T1) to T2 (4 months post T1).
The total score range: 8-40.
Higher scores indicate more emotional social support.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in PROMIS Social Support-Instrumental Support From Baseline to 4-months Post-Baseline
Lasso di tempo: Baseline upon enrollment, Month 4
|
The PROMIS Instrumental Support-Short Form 8a will be used to assess changes in patient and partner reported instrumental support system using a 5-point Likert scale from Baseline (T1) to T2 (4 months post T1).
The total score range: 8-40.
Higher scores indicate more instrumental support.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in Dietary Risk Assessment Scores From Baseline to 4-month Post Baseline as Measured by the Health Promoting Lifestyle Profile II
Lasso di tempo: Baseline upon enrollment, Month 4
|
Change in Dietary Risk Assessment scores used to measure changes in dietary risk from Baseline (T1) to T2 (4 months post T1).
Change from baseline is the post-Baseline values minus the Baseline value.
Participants are asked how often they consume different foods over the past month or week and respond using a Likert Scale ranging from 1=never to 4=routinely.
The total score range: 8-32.
Higher scores indicate better health behaviors in nutrition.
|
Baseline upon enrollment, Month 4
|
Change in Physical Activity Assessment Scores From Baseline to 4-month Post Baseline as Measured by the Health Promoting Lifestyle Profile II
Lasso di tempo: Baseline upon enrollment, Month 4
|
Change in Physical Activity Assessment scores used to measure changes in physical activity from Baseline (T1) to T2 (4 months post T1).
Change from baseline is the post-Baseline values minus the Baseline value.
Participants are asked how often they engage in exercises and physical activity over the past month or week and respond using a Likert Scale, ranging from 1=never to 4=routinely.
The total score range: 9-36.
Higher scores indicate better health behaviors in physical activity.
|
Baseline upon enrollment, Month 4
|
Collaboratori e investigatori
Collaboratori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- LCCC 1619
- 1R21CA212516 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro alla prostata
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Stati Uniti, Singapore, Canada
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
University of ChicagoNational Cancer Institute (NCI)CompletatoAdenocarcinoma pancreatico | Adenocarcinoma gastrico | Adenocarcinoma pancreatico metastatico | Neoplasia gastrointestinale maligna | Cancro al pancreas in stadio III | Cancro al pancreas in stadio IV | Carcinoma della cistifellea | Cancro alla cistifellea in stadio IV | Cancro gastrico in stadio IV | Cancro... e altre condizioniStati Uniti
Prove cliniche su Survivorship Care Plan
-
Jamie StudtsUniversity of Louisville; Bristol-Myers Squibb Foundation; Lung Cancer AllianceCompletatoCancro ai polmoniStati Uniti
-
Baylor College of MedicineThe University of Texas Health Science Center, Houston; University of Texas Southwestern... e altri collaboratoriReclutamentoQualità della vita | Sintomi depressivi | Neoplasia ovaricaStati Uniti
-
Debra FriedmanNational Cancer Institute (NCI)Attivo, non reclutante
-
Wake Forest University Health SciencesCompletatoTumore solido infantile non specificato, protocollo specifico | Pseudomixoma peritoneale | Cancro epiteliale ovarico in stadio IV | Tumore a cellule germinali ovariche in stadio IV | Sarcoma ovarico | Cancro epiteliale ovarico ricorrente | Cancro al colon in stadio IV | Cancro al colon ricorrente | Carcinoma... e altre condizioniStati Uniti
-
Hôpital le VinatierNon ancora reclutamento
-
University of MichiganMichigan Department of Health and Human ServicesTerminatoAssicurazione sanitariaStati Uniti
-
Atatürk Chest Diseases and Chest Surgery Training...ReclutamentoDolore, Postoperatorio | Blocco del piano anteriore del serrato | Chirurgia Toracica Videoassistita | Anestetico localeTacchino
-
MASK-air SASReclutamento
-
Fonds de la Recherche en Santé du QuébecUniversité de MontréalCompletatoIpertensione | Diabete mellito, tipo 2 | Dislipidemie | Colesterolo, LDL | ComorbiditàCanada
-
Norwegian University of Science and TechnologyØstre Toten Municipality; Skien MunicipalityReclutamentoLesioni cerebrali | Deterioramento cognitivoNorvegia